Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models

Oncolytic virus (OV) as a promising therapeutic agent can selectively infect and kill tumor cells with naturally inherited or engineered properties. Considering the limitations of OVs monotherapy, combination therapy has been widely explored. MEK inhibitor (MEKi) Trametinib is an FDA-approved kinase...

Full description

Bibliographic Details
Main Authors: XuSha Zhou, Jing Zhao, Jian V. Zhang, Yinglin Wu, Lei Wang, Xiaoqing Chen, Dongmei Ji, Grace Guoying Zhou
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Viruses
Subjects:
oHSV
MEKi trametinib
BRAF
KRAS
antitumor
Online Access:https://www.mdpi.com/1999-4915/13/9/1758

Internet

https://www.mdpi.com/1999-4915/13/9/1758

Similar Items